Trial Profile

A randomized, double blind, placebo-controlled allergen chamber trial to determine efficacy and safety of INI-2004 compared with placebo in patients with allergic rhinitis in Canada

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Jan 2026 New trial record
05 Jan 2026 According to an Inimmune media release, enrollment in the phase 2 trial is expected to begin this month with topline results expected in late May of 2026. Company intends to expand into a food allergy clinical trial with INI-2004 in early 2027.
05 Jan 2026 According to an Inimmune media release, company announced to start of pivotal phase 2 clinical trial evaluating INI-2004 in patients with allergic rhinitis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com